文献速递肿瘤 PET/CT

全身18F-FDG PET/CT作为首线影像学检查优于CT用于转诊的严重非特异性症状或癌症征象患者:200例随机前瞻性研究

Whole-Body 18F-FDG PET/CT Is Superior to CT as First-Line Diagnostic Imaging in Patients Referred with Serious Nonspecific Symptoms or Signs of Cancer: A Randomized Prospective Study of 200 Patients.
PubMed 文献 · J Nucl Med · 2017-01-12

该随机前瞻性研究纳入200例严重非特异性症状和癌症征象(NSSC)患者,1:1随机接受全身18F-FDG PET/CT或胸腹部CT作为首线影像。18F-FDG PET/CT特异度(96% vs 85%,P=0.028)和准确率(94% vs 82%,P=0.017)均高于CT,敏感度和阴性预测值无统计学显著差异。作者认为该组患者应考虑将18F-FDG PET/CT作为首线影像。

要点

  • 18F-FDG PET/CT较CT特异度更高(96% vs 85%,P=0.028)且准确率更高(94% vs 82%,P=0.017)。
  • 敏感度(83% vs 70%)和阴性预测值(96% vs 92%)无统计学显著差异。
  • 影像提示恶性肿瘤的亚组中,CT组最终诊断延迟较PET/CT组长(11.6 vs 5.7天,P=0.02)。

核心结论

  • 与CT相比,18F-FDG PET/CT在NSSC患者中检测癌症具有更高的诊断特异度和准确率。
  • 作者认为该组患者应考虑将18F-FDG PET/CT作为首线影像学检查。

研究设计与样本

  • 随机前瞻性试验,200例患者按1:1随机分配至全身18F-FDG PET/CT组或胸腹部CT组作为首线影像学检查。
  • 首线影像后建立初步诊断,当资料充分时由医师裁定最终转诊诊断。
  • 197例可分析,3例在扫描前撤回知情同意。

主要发现

  • 39例(20%)诊断为癌症,10例(5%)为感染,15例(8%)为自身免疫性疾病,76例(39%)为其他疾病,57例(28%)未发现特定疾病。
  • 18F-FDG PET/CT特异度高于CT(96% vs 85%,P=0.028),准确率亦高于CT(94% vs 82%,P=0.017)。
  • 敏感度(83% vs 70%)和阴性预测值(96% vs 92%)无统计学显著差异。
  • 按随机分组比较至最终转诊诊断的天数,未见差异(7.2 vs 7.6天)。
  • 影像提示恶性肿瘤的亚组中,CT组至最终诊断的延迟显著长于18F-FDG PET/CT组(11.6 vs 5.7天,P=0.02)。

关键数值与推荐

  • 18F-FDG PET/CT组特异度96% vs CT组85%(P=0.028)。
  • 18F-FDG PET/CT组准确率94% vs CT组82%(P=0.017)。
  • 18F-FDG PET/CT组敏感度83% vs CT组70%,无统计学显著差异。
  • 18F-FDG PET/CT组阴性预测值96% vs CT组92%,无统计学显著差异。
  • 影像提示恶性肿瘤亚组至最终诊断天数:CT组11.6天 vs 18F-FDG PET/CT组5.7天(P=0.02)。

临床怎么用

  • 作者结论认为,与CT相比18F-FDG PET/CT在NSSC患者中检测癌症具有更高的诊断特异度和准确率,该组患者应考虑将18F-FDG PET/CT作为首线影像学检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A fast-track pathway has been established in Denmark to investigate patients with serious nonspecific symptoms and signs of cancer (NSSC), who are not eligible to enter an organ-specific cancer program. The prevalence of cancer in this cohort is approximately 20%. The optimal screening strategy in patients with NSSC remains unknown. The aim of the study was to investigate whether 18F-FDG PET/CT was superior to CT as an initial imaging modality in patients with NSSC. In a randomized prospective trial, the imaging modalities were compared with regard to diagnostic performance. Methods: Two hundred patients were randomized 1:1 to whole-body 18F-FDG PET/CT or CT of the thorax and abdomen as the imaging modality. A tentative diagnosis was established after first-line imaging. The final referral diagnosis was adjudicated by the physician, when sufficient data were available. Results: One hundred ninety-seven patients were available for analysis because 3 patients withdrew consent before scanning. Thirty-nine (20%) patients were diagnosed with cancer, 10 (5%) with an infection, 15 (8%) with an autoimmune disease, and 76 (39%) with other diseases. In the remaining 57 patients (28%), no specific disease was found. 18F-FDG PET/CT had a higher specificity (96% vs. 85%; P = 0.028) and a higher accuracy (94% vs. 82%; P = 0.017) than CT. However, there were no statistically significant differences in sensitivity (83% vs. 70%) or negative predictive values (96% vs. 92%). No difference in days to final referral diagnosis according to randomization group could be shown (7.2 vs. 7.6 d). However, for the subgroups in which the imaging modality showed a suggestion of malignancy, there was a significant delay to final diagnosis in the CT group compared with the 18F-FDG PET/CT group (11.6 vs. 5.7 d; P = 0.02). Conclusion: Compared with CT, we found a higher diagnostic specificity and accuracy of 18F-FDG PET/CT for detecting cancer in patients with NSSC. 18F-FDG PET/CT should therefore be considered as first-line imaging in this group of patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lebech AM, Gaardsting A, Loft A, et al. Whole-Body 18F-FDG PET/CT Is Superior to CT as First-Line Diagnostic Imaging in Patients Referred with Serious Nonspecific Symptoms or Signs of Cancer: A Randomized Prospective Study of 200 Patients. J Nucl Med. 2017. PMID: 28082437. doi:10.2967/jnumed.116.175380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。